Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Hypoxia-inducible factor-1 (HIF-1) is a key target in cancer therapy, particularly for chemoresistant ovarian clear cell carcinoma (OCCC).
• OCCC exhibits poor prognosis due to its resistance to conventional chemotherapy.
• Understanding HIF-1 regulation in OCCC is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the role of HIF-1α in OCCC tumorigenesis.
• To elucidate the molecular mechanisms linking HIF-1 to signaling pathways in OCCC.
• To explore potential therapeutic strategies targeting HIF-1 and associated pathways.

Main Methods:

• Examined HIF-1α expression in ovarian cancer cell lines under normoxia and hypoxia.
• Generated HIF-1α-silenced OCCC cells (RMG-1HKD) to assess proliferation and pathway activity.
• Analyzed the Ras (MEK/ERK) and PI3K (mTOR) pathways using Western blotting and specific inhibitors.
• Evaluated therapeutic efficacy of pathway inhibitors in vivo using xenograft models in nude mice.

Main Results:

• HIF-1α was highly expressed under normoxia in the OCCC cell line RMG-1.
• HIF-1α silencing in RMG-1HKD cells accelerated proliferation and increased Ras pathway activity (MEK/ERK phosphorylation).
• Ras pathway activation was linked to PP2A inactivation and increased MEK phosphorylation.
• Combination therapy with mTOR and MEK inhibitors showed synergistic effects on both RMG-1 and RMG-1HKD cells in vivo.

Conclusions:

• HIF-1 inhibition in OCCC activates the Ras pathway via MEK phosphorylation, mediated by PP2A inactivation.
• The crosstalk between PI3K and Ras pathways presents a therapeutic vulnerability in HIF-1-overexpressing cancers like OCCC.
• Targeting HIF-1 in conjunction with Ras pathway components offers a promising strategy for OCCC treatment.